Succinate dehydrogenase-B fluorescence in situ hybridization in pheochromocytoma-paragangliomas
Open Access
- 29 January 2025
- journal article
- Published by Marmara University in Marmara Medical Journal
- Vol. 38 (1) , 76-83
Abstract
Objective: Preoperative identification of familial pheochromocytoma and paraganglioma (PPGL) is crucial, yet often overlooked, leading to missed diagnoses. Typically, succinate dehydrogenase-B (SDHB) and fumarate hydratase (FH) tests are applied postoperatively to confirm familial links and assess prognosis. However, routine preoperative multidisciplinary collaboration is limited, causing delayed screening requests. Consequently, routine SDHB and FH immunohistochemistry (IHC) testing is not widely practiced. This study introduces SDHB fluorescence in situ hybridization (FISH) as a diagnostic tool, akin to HER2 IHC-FISH testing in gastric carcinomas. Materials and Methods: Succinate dehydrogenase-B and FH IHC were conducted on 43 cases. FISH analysis was performed for 28 cases with suspected familial origin or SDHB IHC loss to determine whether the protein loss was due to chromosomal changes. Results: Complete SDHB IHC loss occurred in 8 cases, partial loss in 4, and preservation in 31. Complete FH loss occurred in 10 cases. FISH analysis revealed chromosomal breaks in 20 cases (71.4%), including those with SDHB/FH IHC loss or positive clinical history. Ten cases (35.7%) showed a “red-signal only” pattern, suggesting further genetic testing. Conclusion: Succinate dehydrogenase-B FISH serves as a cost-effective tool for early PPGL diagnosis, complementing SDHB and FH IHC results. It can help identify cases that need genetic testing, even when IHC results are preserved.Keywords
This publication has 31 references indexed in Scilit:
- Overview of the 2022 WHO Classification of Paragangliomas and PheochromocytomasEndocrine Pathology, 2022
- Apport du pathologiste dans les prédispositions héréditaires aux paragangliomes et phéochromocytomesAnnales de Pathologie, 2020
- COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomasVirchows Archiv, 2019
- Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and ParagangliomaEndocrine Pathology, 2018
- The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromesHuman Pathology, 2018
- SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T)Laboratory Investigation, 2015
- Diagnostic Tests and Biomarkers for Pheochromocytoma and Extra-adrenal Paraganglioma: From Routine Laboratory Methods to Disease StratificationEndocrine Pathology, 2011
- Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromesHuman Pathology, 2010
- An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysisThe Lancet Oncology, 2009
- Mitochondrial tumour suppressors: a genetic and biochemical updateNature Reviews Cancer, 2005